Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schenker

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial ResultsAdi Diab, Helen Gogas, Shahneen Sandhu, et al.
The Lancet. Oncology|January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trialLuis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Future Oncology (London, England)|March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagusYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
The New England Journal of Medicine|May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal CancerKohei Shitara, Elena Elimova, Tianshu Liu, et al.
Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
The New England Journal of Medicine|November 27, 2024
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal CancerThierry Andre, Elena Elez, Eric Van Cutsem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung CancerHossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial ResultsAdi Diab, Helen Gogas, Shahneen Sandhu, et al.
The Lancet. Oncology|January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trialLuis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Future Oncology (London, England)|March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagusYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
The New England Journal of Medicine|May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal CancerKohei Shitara, Elena Elimova, Tianshu Liu, et al.
Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
The New England Journal of Medicine|November 27, 2024
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal CancerThierry Andre, Elena Elez, Eric Van Cutsem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung CancerHossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Pageof 10